Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2018 17:04 ET | Source: Trevena Inc.

Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome

CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic...
October 11, 2018 07:00 ET | Source: Trevena Inc.

Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain

CHESTERBROOK, Pa., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug...
October 01, 2018 07:00 ET | Source: Trevena Inc.

Trevena announces completion of leadership transition and appointment of new director

– Carrie Bourdow assumes CEO position and joins Board of Directors – – Maxine Gowen, Ph.D., retires as CEO, remains on Board of Directors – – Scott Braunstein, M.D., appointed to Board of Directors...
September 10, 2018 16:01 ET | Source: Trevena Inc.

Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018

CHESTERBROOK, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Anesthetic and...
August 30, 2018 16:30 ET | Source: Trevena Inc.

Trevena to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

CHESTERBROOK, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today, announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global...
August 02, 2018 07:00 ET | Source: Trevena Inc.

Trevena Reports Second Quarter 2018 Financial Results

– Oliceridine NDA remains on track for a November 2, 2018 FDA decision – – First license agreements for ex-US development and commercialization of oliceridine add potential revenue streams – – Early...
June 28, 2018 16:01 ET | Source: Trevena Inc.

Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

– Pharmacokinetics, safety, and tolerability support advancement of TRV250 to Phase 2 – – Data suggest potential for TRV250 to be the first selective delta receptor modulator – CHESTERBROOK, Pa.,...
June 11, 2018 16:01 ET | Source: Trevena Inc.

Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires

CHESTERBROOK, Pa., June 11, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) announced today the recent additions of three key members to its leadership team. The Company has appointed Linda...
May 30, 2018 16:01 ET | Source: Trevena Inc.

Trevena to Present at the Jefferies Global Healthcare Conference

CHESTERBROOK, Pa., May 30, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 6th, 2018,...
May 22, 2018 07:00 ET | Source: Trevena Inc.

Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

CHESTERBROOK, Pa., May 22, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced two presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting,...